PartneringWe offer formulation development collaboration and product-specific licenses for a broad spectrum of protein-based therapeutics.
Formulating highly concentrated biopharmaceuticals present challenges in the industry due to viscosity. Most biologics are dosed intravenously and require multiple dosing regimens because these viscous materials require prolonged infusions. Subcutaneous injection is an advantageous, even preferable route, but viscosity interferes with injecting large doses through fine-gauge needles.
ReForm Biologics helps our partners address these challenges. ReForm offers a portfolio of science-based platforms to assist our partners in meeting their product development goals and their patients’ needs for well-tolerated therapies.
We are focused on establishing significant and effective collaborations. ReForm structures its partnerships in an open and science-driven manner, to collaborate with pharmaceutical companies as they develop innovative biologic treatments. ReForm has conducted studies with a number of biotechnology and biopharmaceutical companies.
Upcoming Partnering Events:
JP Morgan Healthcare Conference – January 8-11, 2018
- ReForm Biologics will be in San Francisco from January 8-11, 2018 during the JP Morgan Healthcare Conference to meet with interested companies.
- To schedule a meeting with ReForm Biologics, contact email@example.com.
For more information on partnering and business development, contact us at: firstname.lastname@example.org